ClinicaliQ Trial Snapshot
- JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer — Recruiting • Phase III • Oncology • NCT02468024.
- What is being tested: A comparison of stereotactic ablative radiotherapy (SAbR) versus surgical sublobar resection (SR) to determine which approach provides superior survival outcomes in patients with early-stage non-small cell lung cancer (NSCLC).
- Patient eligibility overview: High-risk operable patients with Stage I NSCLC who are deemed suitable candidates for both treatment modalities; this typically includes elderly patients, those with compromised pulmonary function, or those with significant comorbidities who would not tolerate lobectomy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Eligibility Snapshot
- 0 Inclusion Criteria 1.1 Age > 18 years. 1.2 ECOG/Zubrod performance status (PS) 0, 1, or 2 (reference Appendix C). 1.3 Radiographic findings consistent with non-small cell lung cancer, including lesions with ground glass opacities with a solid component of 50% or greater. 1.4 The primary tumor in the lung must be biopsy confirmed non-small cell lung cancer within 180 days prior to randomization. 1.5 Tumor ≤ 4 cm maximum diameter, including clinical stage IA and selected IB by PET or PET integrated with a simultaneous CT scan (PET-CT) of the chest and upper abdomen performed within 180 days prior to randomization (reference Appendix A & B). Repeat imaging within 90 days prior to randomization is recommended for re-staging but is not required based on institutional norms. 1.6 All clinically suspicious mediastinal N1, N2, or N3 lymph nodes (> 1 cm short-axis dimension on CT scan and/or positive on PET scan) confirmed negative for involvement with NSCLC by one of the following methods: mediastinoscopy, anterior mediastinotomy, EUS/EBUS guided needle aspiration, CT-guided, video-assisted thoracoscopic or open lymph node biopsy within 180 days of randomization. 1.7 Tumor verified by a thoracic surgeon to be in a location that will permit sublobar resection.…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.